Inhibitors of NO-synthases

The substances of the invention are highly effective low-molecular NO-synthases inhibitors. They can be synthesised easily and inexpensively in high purity via standard methods and exhibit selectivity for the bNOS present in the central nervous system which is involved in neuronal diseases as Alzheimer’s and Parkinson’s disease, multiple sclerosis and migraine. Thus, it is of particular importance that the inhibitors, after oral up-take and subsequent resorption via the intestinal epithelium, are able to cross the blood-brain barrier.

Further Information: PDF

Patent- und Verwertungsagentur für die Wissenschaftlichen Einrichtungen in Schleswig-Holstein GmbH (PVA SH)
Phone: +49 (0)431/8009937

Contact
Dr. Alexandra Baumgartner

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Lighting up the future

New multidisciplinary research from the University of St Andrews could lead to more efficient televisions, computer screens and lighting. Researchers at the Organic Semiconductor Centre in the School of Physics and…

Researchers crack sugarcane’s complex genetic code

Sweet success: Scientists created a highly accurate reference genome for one of the most important modern crops and found a rare example of how genes confer disease resistance in plants….

Evolution of the most powerful ocean current on Earth

The Antarctic Circumpolar Current plays an important part in global overturning circulation, the exchange of heat and CO2 between the ocean and atmosphere, and the stability of Antarctica’s ice sheets….

Partners & Sponsors